Nino Maghradze

Nino Maghradze

Auto-generated profile, based on publicly available information

Nino Maghradze

Swiss Tropical and Public Health Institute

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
TPTheresa Pfurtscheller
Theresa Pfurtscheller
ATAna Tsutsunava
Ana Tsutsunava
NMNino Maghradze
Nino Maghradze
MGMariam Gujabidze
Mariam Gujabidze
NBNino Bablishvili
Nino Bablishvili
AGAnkur Gupta-Wright
Ankur Gupta-Wright
Background: Xpert MTB/XDR (Cepheid) is recommended by the World Health Organization for drug susceptibility testing in patients with tuberculosis, with potential for rapid detection of isoniazid and fluoroquinolone resistance. However, diagnostic accuracy and clinical utility in a programmatic setting are unknown. Methods: We evaluated the accuracy and clinical utility of Xpert MTB/XDR in patients with rifampicin-resistant pulmonary tuberculosis during programmatic implementation in Georgia between July 2022 and August 2024, using phenotypic drug susceptibility testing (DST) as a reference standard. Results: An overall 140 patients were tested with Xpert MTB/XDR and phenotypic DST, and 94.9% and 33.8% had isoniazid and fluoroquinolone resistance by phenotypic DST, respectively. Xpert MTB/XDR showed 99.2% sensitivity (95% CI, 95.5%–100%) and 100% specificity (95% CI, 54.1%–100%) for isoniazid resistance. Sensitivity and specificity for fluoroquinolone resistance were 88.4% (95% CI, 74.9%–96.1%) and 100% (95% CI, 95.6%–100%). When indeterminate/invalid Xpert MTB/XDR results were included, 17.4% (8/46) and 6.2% (8/129) of patients with phenotypic fluoroquinolone and isoniazid resistance were missed. Median turnaround time for Xpert MTB/XDR was 1 day (IQR, 1–3) and median time to treatment was 4 days (IQR, 1–7). Phenotypic DST results took a median 43 days (IQR, 29–63) longer than Xpert MTB/XDR results. Finally, 95% (115/121; 95% CI, 89.5%–98.2%) of patients had fluoroquinolones appropriately prescribed based on Xpert MTB/XDR results. Conclusions: Programmatic data confirm the high accuracy of Xpert MTB/XDR, despite being below the World Health Organization target product profile targets for fluoroquinolones, with significantly faster time to results than phenotypic DST.

15 July 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NMNino Maghradze
Nino Maghradze
CLChloé Loiseau
Chloé Loiseau
GGGalo Adrian Goig
Galo Adrian Goig
NBNino Bablishvili
Nino Bablishvili
LJLevan Jugheli
Levan Jugheli
SGSebastien Gagneux
Sebastien Gagneux
Introduction: Resistance to bedaquiline – a novel, promising medication against tuberculosis (TB), is already emerging, and uncertainties regarding the role of the different resistance-conferring mutations complicate the development of molecular diagnostic tools for detecting resistance. Mutations in the three genes atpE, pepQ, and Rv0678 have been associated with increased minimum inhibitory concentrations (MICs) to bedaquiline in Mycobacterium tuberculosis (Mtb). Here, we studied the effect of known and novel mutations in these genes on the phenotypic susceptibility to bedaquiline in Mtb isolates from patients with drug-resistant TB in the country of Georgia. Methods: We used retrospective Mtb isolates (2011–2019) with whole-genome sequencing data, and prospectively collected diagnostic isolates with phenotypic resistance (2019–2022) to bedaquiline at the Georgian National Reference Laboratory. We determined bedaquiline MIC values using the SensititreTM MYCOTB MIC plate. MIC of 0.12 μg/mL was defined as borderline and MIC ≥ 0.25 μg/mL as a resistant isolate. A phylogeny was inferred to assess the likely role of the identified variants in bedaquiline resistance, while taking into consideration population structure of the strains analyzed. Results: We analyzed a total of 69 Mtb isolates and identified 61 mutations across the three target genes. Seventeen (27.8%) of these variants were associated with borderline (0.12 μg/mL) or resistant (≥0.25 μg/mL) MICs to bedaquiline. In addition to six previously described bedaquiline resistance-conferring mutations in atpE and Rv0678, we identified two novel variants in Rv0678 (Leu95Ser and Ile108fs) likely involved in bedaquiline resistance. We found a Tyr92Cys mutation in Rv0678 in two epidemiologically linked isolates, which likely emerged as a consequence of previous exposure to clofazimine. Conclusion: Consistent with previous reports, our study confirms that mutations in Rv0678 are the most frequent cause of bedaquiline resistance in Georgia, in addition to an increasing clinical relevance of mutations in atpE, while the role of pepQ mutations remains to be defined.

30 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
GGGalo A. Goig
Galo A. Goig
CLChloé Loiseau
Chloé Loiseau
NMNino Maghradze
Nino Maghradze
KMKakha Mchedlishvili
Kakha Mchedlishvili
TATeona Avaliani
Teona Avaliani
SGSebastien Gagneux
Sebastien Gagneux
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB are threatening global TB control. The World Health Organization has recently endorsed new regimens for the treatment of MDR-TB that rely on the new and repurposed drugs bedaquiline, pretomanid and linezolid with or without moxifloxacin (BPaL(M)). As BPaL(M) is being rolled-out, resistance to these new drugs is already emerging, leading to acquired XDR-TB. Importantly, instances of transmitted XDR-TB have been reported. The spread of highly drug-resistant M. tuberculosis (MTB) strains pose at risk novel TB treatments that took decades to develop. In this study, we analyzed 6,926 MTB genomes from a 13-year nationwide study in Georgia, a known geographical hotspot of MDR-TB, together with more than 80,000 MTB genomes from public sources to estimate the relative contribution of transmission to the burden of XDR-TB. We show that XDR-TB is already geographically widespread, occurring in at least 27 countries across four continents. Moreover, we estimated that a quarter of the XDR-TB cases identified are likely the consequence of transmission. Our findings call for urgent improvements in the global diagnostic capacity, infection control, and surveillance of XDR-TB.

21 January 2025 in medRxiv
Verified
Preprint
Open access
PDF file
GGGalo A. Goig
Galo A. Goig
CLChloé Loiseau
Chloé Loiseau
NMNino Maghradze
Nino Maghradze
KMKakha Mchedlishvili
Kakha Mchedlishvili
TATeona Avaliani
Teona Avaliani
SGSebastien Gagneux
Sebastien Gagneux
Tuberculosis (TB) remains a major public health concern. Improving TB control programmes and treatment success rates requires a deeper understanding of the factors that determine disease presentation and patient treatment outcomes. While the demographic and clinical factors influencing treatment outcomes are well documented, the role of bacterial genetics remains limited. In this study, we analyzed the Mycobacterium tuberculosis complex (MTBC) genomes and the associated clinical data from 4,536 TB patients in the country of Georgia covering a period of 13 years. Multivariable modelling confirmed the role of known demographic and clinical factors such as sex, age, body mass index (BMI) and comorbidities in determining treatment outcomes, as well as the efficacy of novel TB treatments containing bedaquiline. In addition, we found that some bacterial variables, including the MTBC lineage, the specific mutations conferring resistance to rifampicin and fluoroquinolones, as well as a high bacterial burden were associated with unfavorable outcomes. GWAS analyses revealed no genetic mutations in the bacteria other than known drug resistance-conferring mutations to be associated with treatment outcomes. However, we found that mutations in the bacterial gene sufD were linked to cavitary disease. Additionally, we observed that mutations in sufD, mutations conferring resistance to rifampicin and fitness compensatory mutations were associated with the bacterial burden within patients. We conclude that both patient and bacterial factors determine disease presentation and clinical outcomes in TB.

3 February 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
PMPaolo Miotto
Paolo Miotto
RCRebecca E. Colman
Rebecca E. Colman
ACAndrea M. Cabibbe
Andrea M. Cabibbe
PRPaola M.V. Rancoita
Paola M.V. Rancoita
FMFederico Di Marco
Federico Di Marco
TRTimothy C. Rodwell
Timothy C. Rodwell
Rapid molecular diagnostics have significantly improved access to tuberculosis (TB) drug resistance detection and reduced turnaround times. However, these tools remain limited in their capacity to generate comprehensive resistance profiles, particularly for newer and repurposed anti-TB drugs. Targeted next-generation sequencing (tNGS) offers a promising alternative, enabling a broader resolution of Mycobacterium tuberculosis genomes and faster reporting compared to phenotypic drug susceptibility testing (DST). We conducted a prospective, cross-sectional, multicenter evaluation of the DeepChek 13-Plex KB Drug Susceptibility Testing (ABL Diagnostics S.A., France) tNGS assay for direct detection of TB drug resistance from clinical sputum samples. The study was performed at three reference laboratories in India, South Africa, and Georgia between April 2021 and June 2022. Adults (≥18 years) with confirmed pulmonary TB were enrolled. Sensitivity and specificity were assessed for key anti-TB drugs against a composite reference standard combining phenotypic DST and whole-genome sequencing. Of 832 participants enrolled, 694 (83.4%) were included in the final analysis. Sequencing was successful in 75.6% of samples. Failure rates were higher in samples with low or very low Xpert MTB/RIF categories. The ABL tNGS workflow showed ≥95% sensitivity for rifampicin, isoniazid, and levofloxacin; 92%–93% for pyrazinamide and moxifloxacin; 88% for ethambutol; and 72%–82% for bedaquiline and clofazimine. Specificity was ≥95% for all drugs. The ABL tNGS workflow enables comprehensive resistance profiling, including for new and repurposed TB drugs. However, higher bacillary loads are required to provide a valid test compared to current class-based tNGS assays recommended by the WHO, thus requiring further improvements. IMPORTANCE: Drug-resistant tuberculosis (TB) threatens progress in global TB control, yet current molecular tests detect resistance to only a few drugs. Targeted next-generation sequencing (tNGS) can read many resistance-related genes at once, offering faster and broader results than conventional culture-based testing. We evaluated a commercial tNGS workflow (DeepChek 13-Plex KB, ABL Diagnostics) for direct detection of drug resistance in sputum samples from adults with pulmonary TB in India, South Africa, and Georgia. Among 832 participants, sequencing produced valid results for most samples with moderate or high bacterial loads. The assay accurately identified resistance to key drugs—including rifampicin, isoniazid, fluoroquinolones, and newer medicines such as bedaquiline and clofazimine—while maintaining high specificity. These findings show that tNGS can deliver comprehensive resistance profiles, supporting tailored treatment for people with drug-resistant TB. Further refinement in sample preparation may expand its use to specimens with lower bacterial counts. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04239326 .

5 October 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ATAna Tsutsunava
Ana Tsutsunava
NTNestani Tukvadze
Nestani Tukvadze
ZAZaza Avaliani
Zaza Avaliani
GGGalo A. Goig
Galo A. Goig
LJLevan Jugheli
Levan Jugheli
NMNino Maghradze
Nino Maghradze
Emerging resistance to delamanid (DLM) and pretomanid (Pa) threatens drug-resistant tuberculosis (DR-TB) treatment outcomes. The lack of rapid molecular diagnostics, due to limited knowledge of resistance-conferring mutations, along with standardization challenges for critical concentrations (CC) in phenotypic drug susceptibility testing (pDST) hinder resistance detection. Here, we explore the correlation between minimum inhibitory concentrations (MICs) and genomic variants of DLM and Pa resistance in Mycobacterium tuberculosis ( Mtb ) . Seventeen Mtb isolates phenotypically resistant to DLM detected through routine pDST using the Mycobacterial Growth Indicator Tube (MGIT) system from 2021–2024 were selected from the National Reference Laboratory biobank in Tbilisi, Georgia. DLM/Pa MICs were determined using the Resazurin Microtiter Assay (REMA) with a DLM concentration range of 0.008–2 µg/ml, and a broader range of 0.125–32 µg/ml was utilized for Pa. To identify mutations associated with DLM/Pa resistance, isolates were subjected to whole genome sequencing (WGS). Of the seventeen Mtb isolates phenotypically resistant to DLM, eight (47%) manifested a MIC value below the DLM CC (0.06 µg/ml), with only one carrying a mutation in a gene associated with DLM/Pa resistance ( fbiC ). Among the remaining nine isolates with MICs above the CC, the premature stop codon mutation W88* in ddn gene predominated, present in five cases and associated with elevated DLM and Pa MICs (0.125–2 µg/ml and 2–8 µg/ml, respectively). Three isolates (19%) harbored novel, previously undescribed genetic variants, all within genes previously linked to resistance DLM/Pa (G35fs in ddn , Q317R and Q279H in fgd1 , and C565W in fbiC ). Our results support DLM and Pa resistance association with W88* and W678G mutations in ddn and fbiC genes respectively, currently graded as “uncertain significance” in the WHO catalogue of Mtb drug resistance-conferring mutations. Additionally, we observed previously undescribed mutations exclusively within genes linked to DLM/Pa susceptibility, prompting further investigation of their role in resistance.